Does Depression Speed Up ASCVD Onset and Treatment? - Medscape
Patients with depression may develop atherosclerotic cardiovascular disease earlier and start treatment more often than those without depression but achieve similar cholesterol control, a study finds.
Current Risk Scores Miss Nearly Half of First Heart Attacks
Nov 25, 2025 · Nearly half of adults with a first myocardial infarction show low or borderline risk on current risk estimators. Most develop symptoms only within 48 hours and would not qualify for statins …
Menopause Linked to Higher ASCVD Risk - Medscape
Aug 26, 2025 · Menopause is independently associated with a higher risk for atherosclerotic cardiovascular disease, with the strongest association seen in women younger than 60 years.
What PCPs Need to Know About the New BP Guidelines - Medscape
Oct 31, 2025 · For individuals with stage 1 hypertension who have established ASCVD, diabetes, CKD, or elevated cardiovascular risk (defined as > 7.5% 10-year risk on the PREVENT equation), …
Less TV Time Cuts ASCVD Risk Despite Genetic Risk for T2D
Mar 20, 2025 · The 10-year absolute risk for ASCVD was lower in individuals with high T2D genetic risk who watched ≤ 1 hour of television daily than in those with low T2D genetic risk who watched ≥ 2 …
Low-Dose Colchicine Approved for CVD: Now What? - Medscape
Jun 22, 2023 · The recent US approval of a new low dose of colchicine 0.5 mg (Lodoco; Agepha Pharma) with a broad indication for use in atherosclerotic cardiovascular disease (ASCVD) …
Uterine Fibroids Linked to Higher ASCVD Risk - Medscape
Uterine fibroids may be a marker for identifying women prone to cardiovascular disease, according to a new longitudinal study.
AACE Publishes Guideline on Drug Management of Dyslipidemia
Feb 13, 2025 · It includes 13 evidence-based recommendations for the pharmacologic management of adults with dyslipidemia, focused on patient-important outcomes of ASCVD risk reduction.
PCSK9 Inhibitor Found Effective for Primary Prevention - Medscape
When added to optimized oral anti-lipid therapy, a PCSK9 blocker provided an additional 25% risk reduction in a first cardiovascular event, new data show.
ESC Dyslipidemia Guideline Update: A US Perspective - Medscape
Oct 1, 2025 · Cardiologist Michelle O'Donoghue interviews Marc Sabatine, who was the US representative on the focused update of the ESC lipid management guidelines.